Stock Price

New data reveals a massive surge in stock futures trading on crypto platforms, led by a 1,000% jump in Micron. Is the AI boom redrawing the map for investors?

A slight dip in Neuberger Private Equity's NAV masks a flurry of strategic moves, from lucrative exits to aggressive buybacks, revealing a playbook for thriving in a disconnected market.

Amid a stock surge, Glass House Brands forces a warrant exercise, a strategic move to inject cash and clean its books for a potential major exchange listing.

A 27% stock plunge and a class action lawsuit have hit Phreesia. But the real story lies in the shifting sands of pharma marketing and SaaS growth promises.

An activist investor challenges Samsung's governance at its security unit, S-1, exposing deep undervaluation and a failure to embrace a connected future.

Westport Fuel Systems secures $10M, but the deal's structure and timing raise questions. Is this the boost needed for its hydrogen goals, or a dilutionary stopgap?

Beyond the 3-for-1 split, Willis Lease Finance Corp's shareholder vote is a powerful endorsement of its strategy in a rebounding aviation services sector.

SCWorx gets a final chance to stay on Nasdaq, but it's pinned on a high-risk reverse stock split—a move that failed just months ago. Can it succeed?

AeroVironment's stock nosedive after a key Space Force contract loss triggers a securities fraud lawsuit, revealing critical risks in M&A and government deals.

Beyond the badge: What Penguin's elite NVIDIA partner status truly means for enterprises building the AI factories of tomorrow and the investors betting on them.

A landmark $335M storage deal between Backblaze and CoreWeave reveals the hidden engine of AI: cost-effective data infrastructure at an exabyte scale.

NewtekOne just automated a tedious part of getting a business loan. But the real story is its plan to sell this tech to other banks, changing its own game.

Illumina's appointment of Eli Lilly's R&D chief isn't just a new hire; it's a strategic masterstroke signaling a deeper push into drug development.

Zodiac Partners has raised its all-cash offer for Destination XL, forcing a showdown as the board's preferred—yet faltering—merger hangs in the balance.

A securities lawsuit over a $100M deal with Redfin has hammered Zillow's stock. It’s a stark lesson in the growing cost of antitrust scrutiny.

A biopharma firm's celebrated 20% growth is now alleged to be a mirage, sparking a fraud lawsuit that questions where the line is drawn between ambition and accountability.

Hyperscale Data builds a $46M Bitcoin treasury while planning a 590MW AI data center empire, forcing a strategic split and raising investor questions.

As traditional chip scaling falters, Qnity Electronics launches a new hub for advanced packaging, a critical 'stacking' technology set to define the future of AI.

With a sub-$10M market cap and blockbuster data, IMUNON's CEO faces a critical test: convince Wall Street its ovarian cancer drug is the real deal.

Cardinal Infrastructure's plan to raise capital caused a stock dip, but it's a strategic move to fuel aggressive expansion in a booming market.